For example, IDH1/2 mutations in adult gliomas and histone H3.1 and H3.3 mutations in pediatric high grade gliomas were shown to be clonal for their respective subtypes, and developing therapies targeting these genetic alterations would reduce the risk of antigen-escape. The gene discussed is IDH1; the disease is glioma.